Spruce Biosciences, Inc. (SPRB)

0,7444 +0,0028 (+0,38%) Börsenschluss: 04:00PM EDT

Spruce Biosciences, Inc.

611 Gateway Boulevard
Suite 740
South San Francisco, CA 94080
United States
415 655 4168
https://www.sprucebiosciences.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 29

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Michael G. Grey	Executive Chairman	70k	N/A	1953
Dr. Javier Szwarcberg M.D., M.P.H.	CEO & Director	951,85k	N/A	1970
Mr. Samir M. Gharib CPA, M.B.A.	President & CFO	683,63k	N/A	1982
Dr. Ralph William Charlton III, M.D.	Chief Medical Officer	647,4k	N/A	1970
Ms. P. J. Ramtin	Senior Vice President of Business Operations	N/A	N/A	N/A
Ms. Heidi Petersen M.P.H.	Senior Vice President of Regulatory & Quality	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Corporate Governance

Spruce Biosciences, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 7, Vorstand: 9, Shareholderrechte: 8, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.